Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8441704 | European Journal of Cancer | 2015 | 23 Pages |
Abstract
Based on this systematic review, there is no strong evidence to support one therapy over another as EBRT, BT and RP can all be considered as effective monotherapies for localised disease with EBRT also effective for post-operative management. All treatments have unique adverse events profiles. Further large, robust RCTs which report treatment-specific and treatment combination-specific outcomes in defined prostate cancer risk groups following established reporting standards are needed. These will strengthen the evidence base for newer technologies, help reinforce current consensus guidelines and establish greater standardisation across practices.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Robert F. Wolff, Steve Ryder, Alberto Bossi, Alberto Briganti, Juanita Crook, Ann Henry, Jeffrey Karnes, Louis Potters, Theo de Reijke, Nelson Stone, Marion Burckhardt, Steven Duffy, Gillian Worthy, Jos Kleijnen,